# ProKidney Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/ProKidney Corp). ## Overview ProKidney Corp. is a U.S.-based clinical-stage biotechnology company focused on developing cell therapies for chronic kidney disease. Its business centers on rilparencel, an autologous renal cell therapy designed to preserve kidney function, along with related manufacturing and clinical development activities in the United States. ## Products & services • Rilparencel autologous renal cell therapy • Clinical development for chronic kidney disease • Cell processing and manufacturing capabilities • Leasing of manufacturing-related facilities - **Cell therapy product candidates** (0%) — Autologous cell-based therapies under clinical development for kidney disease. - **Clinical development services** (0%) — Research, trial execution, regulatory work, and development activities for rilparencel. - **Manufacturing and facility operations** (0%) — Manufacturing infrastructure and related operational activities supporting the therapy platform. - **Lease income** (100%) — Revenue from leasing activities associated with buildings used in operations. - Rilparencel autologous renal cell therapy - Clinical development for chronic kidney disease - Cell processing and manufacturing capabilities - Leasing of manufacturing-related facilities ## Customers ProKidney does not yet sell a commercial product, so its direct end customers are not established in the traditional sense. Its future customer base is expected to include patients with type 2 diabetes and advanced chronic kidney disease, accessed through physicians, nephrology centers, and healthcare systems if rilparencel is approved. The company also may pursue collaboration or license partners that could pay for development or commercialization rights. - **CKD patients** (primary) — Patients with type 2 diabetes and advanced chronic kidney disease who would receive rilparencel if approved. - **Nephrology providers** (primary) — Physicians and specialty care centers that would identify, refer, and administer therapy pathways. - **Strategic partners** (secondary) — Potential collaborators or licensees that could fund development or commercialization. - **Property tenants** (emerging) — Counterparties to the company’s lease arrangements tied to its manufacturing-related buildings. - Patients with type 2 diabetes and advanced chronic kidney disease - Nephrologists and kidney care specialists who would prescribe therapy - Hospitals and specialty clinics treating advanced CKD patients - Potential pharmaceutical or biotech collaboration partners - Tenants under existing building lease agreements ## Geography ProKidney is headquartered in the United States and conducts its manufacturing operations in Winston-Salem, North Carolina. Its development program is centered on the U.S. market, where it is pursuing regulatory approval for rilparencel. The company also has an international corporate history, but its operating footprint is now primarily U.S.-based. - **United States** (100%) — Operating and development focus is primarily U.S.-based; no country revenue split disclosed. - Headquartered in the United States - Manufacturing operations in Winston-Salem, North Carolina - Clinical and regulatory focus on the U.S. market - Corporate structure has included Cayman Islands and Ireland entities - Future commercialization would likely begin in the U.S. ## Strategy ProKidney’s strategy is to advance rilparencel through late-stage clinical development and secure regulatory approval in the United States. It also seeks to maintain manufacturing readiness and preserve optionality through collaborations, licensing, or other strategic transactions while funding development through external capital sources. - **Complete clinical development of rilparencel** (short-term) — Approval depends on demonstrating safety and efficacy in advanced CKD patients. - **Secure regulatory approval in the U.S.** (short-term) — Commercial value depends on FDA review and acceptance of the clinical package. - **Build commercial and manufacturing readiness** (medium-term) — A cell therapy requires controlled production, logistics, and quality systems before launch. - **Preserve financing flexibility** (short-term) — Development-stage biotech requires ongoing external funding before product revenue exists. - Advance rilparencel through late-stage clinical trials - Pursue FDA approval under an expedited pathway - Maintain manufacturing capability for future launch - Seek collaborations or licensing opportunities - Use external capital to fund development and operations ## Risks ProKidney faces the typical risks of a clinical-stage biotech company: trial failure, regulatory delay, and the possibility that its product candidate never reaches commercialization. It also depends on external financing and on maintaining manufacturing and quality systems that meet FDA expectations, while its lease-related revenue is limited and not representative of a commercial operating base. - **Clinical development failure for rilparencel** [critical] — The company’s value depends on positive trial data and eventual approval. - **FDA and regulatory uncertainty** [high] — Approval timing and requirements can change, affecting launch prospects. - **Financing and dilution risk** [high] — The company expects to fund operations through external capital sources. - **Manufacturing and quality compliance** [high] — Cell therapy production requires strict controls and regulatory compliance. - **Government and trade policy disruption** [medium] — Changes in tariffs or agency operations can affect supply chains and oversight. - Clinical trial outcomes may not support approval - FDA review or guidance could be delayed or change - Additional capital may be needed before product revenue - Manufacturing and quality compliance failures could disrupt development - Future commercialization is uncertain and may never occur ## Accounting The company’s reported results are shaped by development-stage accounting, including heavy use of estimates for clinical, regulatory, and manufacturing-related costs. Revenue is limited to lease activity, so investors should watch how lease income, stock-based compensation, and any future collaboration or license arrangements are recognized and measured. - **Lease accounting** — Affects reported revenue and asset utilization - **R&D accruals and estimates** — Affects operating expense timing - **Stock-based compensation** — Affects non-cash operating expense - **Future collaboration revenue** — Could change revenue profile materially - Lease revenue recognition from building lease agreements - Clinical trial and R&D cost accrual estimates - Stock-based compensation and forfeiture assumptions - Fair value judgments for equity awards and financing instruments - Potential future collaboration or license revenue recognition --- *Last updated: 2026-09-24T11:19:59.807332+00:00*